SREBF2 and metabolic syndrome: Apigenin could attenuate dyslipidemia and subsequent atherosclerotic conditions through down-regulating SREBP-1c, SREBP-2, FAS, stearyl-CoA desaturase 1, HMG-CoA reductase, TLR-4, Npc1l1, MyD88, p-IκB-α, and NF-κB p65 which are involved in inflammation and atherosclerotic plaques formation.